Member Info for Adastra

Taken a nice 2 day profit here and plugged into Oxford Nanopore on weakness there. Cheaper price than Novo paid earlier in the week. Great prospects.

Spot on - letting mine ride a while

Looking significantly stronger than the current shareprice reflects. Sensible upward readjustment should follow.

Should steady the ship and kickstart the upswing.

The pathogens that could spark the next pandemic

The World Health Organization has updated its list of most dangerous viruses and bacteria.

https://www.nature.com/articles/d41586-024-02513-3

I'm in at 112p.....too cheap.

Gloves are off for predators on October 5th hence the interest of the big pharmas like BioMerieux and Novo and the constantly repeated fact by the CEO that predators are circling due to low current MCap.

The anti-takeover shares lapse on October 5th

Apologies one A,B and C shares.

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company announces that as at 5 August 2024, the Company's issued share capital consisted of 940,896,164 Ordinary Shares, one class A limited anti-takeover ("LAT") share of £1.00, one class B LAT share of £1.00 and one class C LAT share of £1.00.

Those shares expire on October 5th....

Yesterday's market turmoil hid the very significant Oxford Nano RNS regarding use of proprietary long chain DNA sequencing in Singapore. Significant in that ONT long chain sequencing is unique in opening the gate to personalised medicine. Oxford Nano is providing the picks and shovels to unlock this biological goldmine. That's why FOMO has caused BioMerieux and Novo to jump on board with shareholdings. The CEO continues to reiterate the vulnerability of the company to big pharma takeover which is why he built in 3 year anti-takeover protection in 2021 using a single B and C shares.

It's the highlighting of the potential of ONT long chain sequencing over eg Illumina short chain. Personalised medicine is the game changer for all big pharmas and this news really shows why the likes of BioMerieux and Novo are investing. Takeover protection ends October 5th - let the games begin.

Thanks. It's the highlighting th

Significant RNS not being highlighted on LSE site.

Why is ONT tracking the wider market down when news like this is a huge endorsement of potential here. Very happy to mop up more shares at this below Novo level.....crazy.

Thank you for todays market drop..I'll have some more of these!! Perfect. Now you can reflect true value....onward and upward

Thank you for todays market drop..I'll have some more of these!! Perfect. Now you can reflect true value....onward and upward

Oxford Nanopore Technologies plc

Oxford Nanopore to sequence 10,000 genomes for Singapore's National Precision Medicine (NPM) programme

Https://www.gbnews.com/health/bird-flu-uk-pandemic-symptoms

Surveillance helps us identify and monitor strains with zoonotic potential. A tracheal swab from a pelican on a Peruvian beach was H5N1 positive (clade 2.3.4.4b) using Oxford Nanopore’s MinION platform. The near-complete genome sequence of strain VFAR-140 will aid us in understanding avian influenza epidemiology and spread.

Your buy at 1.34 will probably look excellent as October nears. Few sensible investors buy at the bottom of a cycle, preferring to wait till an upswing is established and then buy in tranches. The outlook AND peer pharma interest is gaining momentum as BioMerieux and Novo have noticed and taken preliminary stakes. BOTH have indicated their desire to increase their holdings in the future. That is certainly not indicative of a falling shareprice rather a temporary pullback after the initial strong rises. The amount of data being generated by Oxford Nano is snowballing as are the applications. As I said previously, nVidia provided the picks and shovels for the AI rush. Oxford Nanopore is doing precisely the same for the BI rush....Biological Intelligence. Hold tight and increase exposure on the dips imo.....works for me. ONT is definitely in the ascendancy.

Patience. The share price is now on a positive trajectory after recent lows. A pullback is to be expected but this should prove temporary due to the big increase in buyers getting on board at each high. Newsflow on X is fast and cutting edge and Oxford Nano is now attracting big stable pharmas wanting a shareholding in the Company. With just 2 months to go till the 3 year anti-takeover provision in the IPO ends, expect more volatility. Given the more than adequate cash runway and escalation in product placement and use the CEO has repeatedly indicated vulnerability to larger predator(s). The fear of missing out on a share with multibag potential in the near term will certainly attract comment and position taking imo.